Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 355

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 355
---
 board of directors because of his extensive executive leadership
experience in the biopharmaceutical industry, including his service at Pfizer, and his experience serving on public company boards.

72

Michael
J. Newman, Ph.D. has served as our Chief Scientific Officer and a member of our board of directors since August 2021. Dr. Newman
is a pharmaceutical/biotechnology executive with over 40 years of experience carrying out and managing oncology research and development,
in addition to undergraduate and graduate research and training in microbiology. He was the Founder, President, Chief Executive Officer
and a member of the board of directors of Decoy (from August 2013 to August 2021). His previous positions also include faculty appointments
in Biochemistry at Brandeis University (from 1984 to 1987) and the Roche Institute of Molecular Biology (from 1987 to 1992), Senior Associate
Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), and Executive Director of Oncology at Novartis Pharmaceuticals
(Head of Cancer Biology in the U.S.) (from 1992 to 1997), and senior management at several Biotechnology companies (from 1998 to 2012).
Dr. Newman received a bachelor’s degree in Biology from the University of California at San Diego, a Ph.D. in Cell and Developmental
Biology from Harvard Medical School (National Science Foundation Pre-Doctoral Fellow), and carried out post-doctoral research at Cornell
University. We believe that Dr. Newman is qualified to serve on our board of directors because of his extensive scientific and research
background, as well as his experience as founder and CEO of Decoy.

Nir
Sassi has served as our Chief Financial Officer since July 2021 and served as Intec Israel’s Chief Financial Officer from
March 2010 until the Merger (other than from January 2015 to August 2016, during which period Mr. Sassi served as Intec Israel’s
VP Finance), and its President from March 2021 until the Merger. Prior to his service with Intec Israel, Mr. Sassi served as a Senior
Manager at PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2010, including two years relocation to the PricewaterhouseCoopers
New York office. Mr. Sassi is a certified public accountant in Israel and has a bachelor’s degree in economics and accounting from